Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2004

View Archived Issues

Selective GABA-A alpha3 receptor subtype agonist and diazepam show comparable effects in vivo

Neurocognitive benefits of methylphenidate in children who survive leukemia or brain tumors

Triage D-Dimer test cleared for use

European MAA submitted for Cubicin

NT-proBNP test cleared for use in two new indications

Buprenorphine analogue inhibits morphine-induced behavioral sensitization in mice

Nonpeptide orally available SK channel blockers for gastrointestinal motility disorders

Orally active cathepsin inhibitor effective against osteoporosis in vivo

Study on effects of RWJ-333369 support use of chronic models in antiepileptic drug discovery

Endovasc reports positive drug delivery findings

PhytoMedical enters CRADA to synthesize type 2 diabetes compounds

FibroGen reports positive findings for oral anemia therapy FG-2216

Fast track status for AMG-531 in immune thrombocytopenic purpura

AMG-706 awarded fast track status

Maxygen announces new development program, reprioritizes pipeline

CytRx investigates two distinct approaches for treatment of ALS

Preclinical studies support the use of MLN-518 in AML

New data on the neurophysiological effects of talampanel in humans

Update on the safety and antiepileptic effects of retigabine

TaiGen claims novel series of chemokine receptor modulators

New benzimidazole derivatives for CNS disorders under study at NeuroSearch

Novartis researchers design new immunosuppressant and antiinflammatory agents

Scientists at Predix report 5-HT2B receptor modulators for CNS and vascular disorders

New compounds acting on melanocortin receptors reported by SCRAS

Gamma-secretase inhibitors identified at Merck

Aryplase submitted for European approval

Clinical responses seen in phase I/II study of Humax-CD20 in NHL

BioVisioN spins off ImVisioN

Medarex and PharmAthene to develop and commercialize MDX-1303

Topline results from phase III study of edifoligide for peripheral bypass graft

LAB International plans phase II study of GHRH analogue

Endovasc plans phase III trial for Liprostin in 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...